

- **Name:** In Hee Lee
 - **Current Position & Affiliation:** Assistant professor,
Department of Hematology & Oncology,
Kyungpook National University Chilgok
Hospital
 - **Country:** Korea
-

- **Educational Background:**

Mar. 2003-Feb.2005 Pre-medicine, Daegu Catholic University College of Medicine, Daegu, Korea

Mar. 2005-Feb.2009 M.D, Daegu Catholic University College of Medicine, Daegu, Korea

2016-2018 M.S. Kyungpook National University School of Medicine, Daegu, Korea

2019~2021 Ph.D. Kyungpook National University School of Medicine, Daegu, Korea

- **Professional Experience:**

2016-2018 Clinical Fellow, Kyungpook National University Chilgok Hospital, Daegu, Korea

2018-2019 Clinical Assistant Professor, Kyungpook National University Chilgok Hospital, Daegu

2019-2021 Assistant Professor, Daegu Catholic University School of Medicine, Daegu, Korea

2021~2023 Clinical assistant professor, Kyungpook National University Chilgok Hospital, Daegu

2023~ Assistant professor, Kyungpook National University Chilgok Hospital, Daegu, Korea

- **Professional Organizations:**

Member, Korean Society of Medical Oncology (KSMO)

Member, Korean Cancer Study Group (KCSG)

Member, Korean Cancer Association (KCA)

Member, Korean Gynecologic Oncology Group (KGOG)

Member, ASCO

Member, ESMO

March 2021– December 2023 Secretary of GY cancer Committee, KCSG

May 2024 – Present Member, General Affairs Committee, KSMO

• Main Scientific Publications:

1. **Lee IH**, Kim EA, Lee SJ, Kang B, Lee J, Jung JH, Park HY, Park JY, Park NJY, Kang J, Chae YS. The Role of EMP2 in Triple-negative Breast Cancer. *Anticancer Res.* 2025 Jul 45(6): 2417-2427
2. **Lee IH**, Lee SJ, Kim J, Lee YH, Chong GO, Kim JM, Lee J, Lee NY, Park SY, Hong DG, Chae YS Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer. *Cancer Chemother Pharmacol.* 2024 Jul 94(1): 103-108
3. **Lee IH**, Lee SJ, Kang B, Lee J, Jung JH, Park HY, Park JY, Park NJY, Kim EA, Kang J, Chae YS. Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer. *Breast Cancer Res Treat.* 2024 May 205(1): 181-191.
4. **Lee IH**, Jung JH, Lee SJ, Lee J, Park HY, Park JY, Park JY, Jung JH, Lee H, Jeon HS, Chae YS. Evaluation of a Direct Reverse Transcription Loop-Mediated Isothermal Amplification Method without RNA Extraction (Direct RT-LAMP) for the Detection of Lymph Node Metastasis in Early Breast Cancer. *Cancer Res Treat.* 2022 Jan 54(1): 174-181.
5. Lee SJ, **Lee IH**, Kim S, Lee JM, Chae YS, Park HK. Effectiveness of Carboplatin-Prescreening Intradermal Skin Tests to Reduce Unanticipated Immediate Hypersensitivity Reactions: A Comparative Study. *J Allergy Clin Immunol Pract.* 2024 Apr 12(4): 998-1005.e1003.
6. Kim M, Shim HS, Kim S, **Lee IH**, Kim J, Yoon S et al. Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP. *Cancer Res Treat.* 2024 Jul 56(3): 721-742.
7. Yoon S, Kim M, Hong YS, Kim HS, Kim ST, Kim J, Yun H, Yoo C, Ahn HK, Kim HS, **Lee IH**, Kim IH, Park I, Jeong JH, Cheon J, Kim. Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. *Cancer Res Treat* 2022 Jan 54(1): 1-9.
8. Maeng CH, Park I, **Lee IH**, An HJ, Shim HJ, Lee SC .Barriers to Clinical Trial Enrollment: KCSG Survey-Based Perspectives of Medical Oncologists, Patients, and Their Caregivers. *Cancer Res Treat.* 2025 Jul